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Factor VIII and Factor IX in a Twin Population.
Evidence for a Major Effect of ABO Locus on Factor VIII Level
K. H. 0RSTAVIK,l P. MAGNUS,I H. REISNER,2 K. BERG,' J. B. GRAHAM,2
AND W. NANCE3
SUMMARY
In order to establish the relative importance of genetic factors on the
variation in plasma concentration of coagulation factors VIII and IX,
these parameters were determined in 74 monozygotic and 84 like-sexed
dizygotic twin pairs. The twins belonged to two age groups: 33-39
years and 57-62 years. Factor VIII was determined as factor VIII co-
agulant antigen (VIIICAg) and as factor VIII-related antigen (VIIIRAg).
Factor IX was determined as factor IX antigen (IXAg). A higher value
for each coagulation factor was found in the older-age group compared
to the younger group, whereas no difference was found between the
sexes. A significant correlation was found between values for VIIIRAg
and VIIICAg (r = .56). For VIIICAg, it could be demonstrated that the
age effect was secondary to the age effect on VIIIRAg. The concentration
of VIIICAg and VIIIRAg varied among ABO blood types, being lowest
in type 0 individuals, higher in A2 individuals, and highest in Al and
B individuals. The effect of the ABO locus on VIIICAg was secondary
to an effect on VIIIRAg. Analysis of variance revealed a significant
genetic influence on the variance of VIIICAg and VIIIRAg with a her-
itability estimate of .57 for VIIICAg and .66 for VIIIRAg. This is in
agreement with a previous hypothesis of an effect of several autosomal
genes on factor VIII concentration. Thirty percent of the genetic variance
of VIIIRAg was due to the effect of ABO blood type. The ABO locus
is therefore a major locus for the determination of factor VIII concen-
tration. No significant genetic effect on the variation in plasma concen-
tration of IXAg could be detected.
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Patients with hemophilia A or B have a deficiency of coagulation factor VIII or
IX activity. The plasma concentration of factors VIII and IX show a very wide
range in individuals without a bleeding disorder. Several nongenetic factors are
known to influence the level of these coagulation factors [1]. A genetic influence
on the level of factor VIII has been indicated by family studies [1, 2]. These
studies were in agreement with the hypothesis that the level of factor VIII in
individuals without a bleeding disorder is determined by a series of genes on
autosomes. A recent study from Sardinia, however, suggests that this variation
is controlled by a series of normal isoalleles on the X chromosome [3]. Twin
studies may give an estimate of the relative importance of genetic factors on the
variation in concentration of a plasma protein by comparison of monozygotic
(MZ) and dizygotic (DZ) twins. One previously reported twin study [1] failed to
detect a genetic effect on factor VIII concentration. Another twin study [4] showed
evidence of a significant genetic effect on factor VIII concentration but not on
factor IX concentration. Since only a small number of twin pairs was included,
a heritability estimate could not be established.
The family studies referred to above have been based on determination of the
coagulant activity of the factors (VIIIC and IXC). Plasma factor VIII is a complex
of two distinct proteins: a small factor VIII coagulant protein (VIIICAg) and a
large carrier molecule, factor VIII-related protein (VIIIRAg), which are under
separate genetic control [5]. Immunization of laboratory animals with purified
factor VIII complex results in antibodies against VIIIRAg. Replacement therapy
in hemophilia A patients, who are deficient in the coagulant activity of factor
VIII, may result in the production of antibodies to VIIICAg. Here, we present
the results of a twin study of the plasma concentration of VIIICAg, VIIIRAg,
and factor IX protein (IXAg).
MATERIALS AND METHODS
Twins
Plasma were examined from 158 MZ or like-sexed DZ twin pairs. The twins were either
33-39 or 57-62 years old and belonged to a subgroup of pairs of known zygosity drawn
from a population-based Norwegian twin panel [6] (table 1). Zygosity had been determined
by testing for the blood group antigens A, Al, B, C, c, D, E, e, M, N, S, s, P, Fya, Fyb,
Lua, Lub, Kell, Jk', and Jkb and for the electrophoretic variants C3 and Hp. The probability
of monozygosity was more than .99 for twin pairs concordant for each genetic marker.
All twins had responded to a questionnaire that included questions on their health, but no
specific questions about bleeding disorders. Included in the material was also plasma from
17 members of twin pairs, where plasma from the cotwin was not available. Values on
these twins were included in the study of associations to genetic markers and for the
calculation of the correlation between VIIIRAg and VIIICAg.
Plasma
The twins were bled in the laboratory or in their homes after an overnight fast. Blood
was collected into evacuated blood-collecting tubes (Venoject) containing 1/10 vol 3.13%
sodium citrate and was kept at 40C for no more than 4 hrs before the separation of plasma.
This was done by centrifugation at 2,000 g for 30 min at 40C. The plasma samples were
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TABLE 1
DISTRIBUTION OF AGE, SEX, AND ZYGOSITY IN 158 TWIN PAIRS
33-39 YEARS 57-62 YEARS
ZYGOSITY Males Females Males Females TOTAL
MZ ... 19 18 16 21 74
DZ ... 15 21 23 25 84
Total .. 34 39 39 46 158
stored at -70'C until they were tested. A standard plasma was prepared by pooling equal
volumes of plasma from 20 healthy individuals. This standard plasma was defined to
contain 100% of each coagulation factor.
VIIICAg
VIJICAg was determined by a radioimmunoassay using a human antibody [7]. The
samples were shipped frozen on dry ice from Oslo, and each sample was tested diluted
1/10 in duplicate at the University of North Carolina at Chapel Hill. For some of the twins,
plasma was not available for VIIICAg assay.
VIIIRAg and IXAg
VITIRAg and IXAg were determined by the "rocket" electroimmunoassay technique
of Laurell in the laboratory in Oslo. The antiserum to factor VIII was prepared by im-
munization of rabbits with purified factor VIII (a gift from Lars Holmberg, Coagulation
Laboratory, Allmanna Sjukhuset, Malmo, Sweden). This antiserum was monospecific as
judged by double-immunodiffusion technique. Antiserum to factor IX was prepared as
described [8, 9]. Each plasma sample was tested undiluted and diluted 1/2, in both cases
in duplicate. The median of four values was chosen for further analysis. The detailed
experimental conditions for the electroimmunoassay were as described [10]. The study
was conducted blindly. Thus, the zygosity of the twins was unknown until all the samples
had been analyzed.
Statistical Methods
For the studies of associations to genetic markers and for the calculation of the correlation
between VIIIRAg and VIIICAg, a random sample of one member of each twin pair was
used. This was done since the values on the two twins in a pair are not independent
observations in genetic terms. F-test, linear regression, and z-scoring were performed as
described in standard textbooks. For the estimation of genetic variance and its relative
influence on total variance (heritability), a model-fitting approach was used [1 1].
The mean squares obtained from ordinary one-way analysis of variance for each twin
type is interpreted as sums of the variance components. The mean squares within (MSw)
and between (MSB) twin pairs are connected to the variance components within (Vw) and
between (VB) pairs as shown by Winer [12].
Mean squares Degrees of freedom Variance
MSW . n VW
MSB . n - I Vw + 2VB




MODEL FOR GENETIC (VG) AND ENVIRONMENTAL (VEw and VEB)
VARIANCES FOR MEAN SQUARES OBTAINED FROM ANALYSIS OF
VARIANCE IN MZ AND DZ TWIN PAIRS
Observed
mean square Variante Model
MSWMZ.. VW VEW
MSBMZ ... . VW + 2 VB VEW + 2(VG + VEB)
MSwDZ .. . VW VEW + 1/2 VG
MSBDZ ... . VW + 2 VB VEW + 1'/2 VG + 2 VEB
NOTE: MSWMZ = mean square within MZ twin pairs, MSBMZ = mean
square between MZ twin pairs, MSWDZ = mean square within DZ twin pairs,
MSBDZ = mean square between DZ twin pairs.
It is assumed that the observed total variance is the sum of variance components of
additive genetic (VG) and environmental (VE) origin. The environmental variance may be
divided into two parts: environmental variance within twin pairs (VEW) and environmental
variance between twin pairs (VEB). VEW represents environmental effects that are specific
to each individual and will also include error variance. VEB represents environmental
effects that are common to the two members of a twin pair.
The variance within MZ twin pairs is the same as VEW since environmental influences
within families is the only variation source that can make MZ twin pairs different. The
variance between MZ twin pairs on the other hand is the sum of VG and VEB. Furthermore,
the variance within DZ twin pairs is due to both genotypic and within family environmental
variance. Since DZ twins share half their genes, this variance is the sum of 1/2 VG and
VEW. The variance between DZ pairs may be due to both genotypic and between pairs
variance (table 2).
Genetic and environmental variance components with their standard errors were estimated
by the method of weighted least squares [11]. The goodness of fit of the model was
evaluated after calculation of the weighted sum of squared deviations of the expected
mean squares from the observed values. This statistic follows the chi-square distribution.
A simple presentation of this model has been presented by Sundet et al. [13].
RESULTS
Distribution of Values
The distribution of the plasma concentration of VIIIRAg, VIIICAg, and IXAg
in the total material is demonstrated in figures 1, 2, and 3. The distributions of
VIIICAg and VIJIRAg differed significantly from normality. Normality was ob-
tained after logarithmic transformation and the natural logarithm was used for
all statistical analyses.
Thirteen individuals had VIIIRAg values below 40%. The health questionnaire
had been returned by eight of these individuals. None of them reported symptoms
of any serious disorder or bleeding episodes. Four individuals, including the
individual with a plasma concentration of VIIIRAg of only 19%, had undergone
surgery uneventfully.
The older-age group had significantly higher values for all three parameters
than the younger-age group (table 3). This age effect was seen in both males and
females, and no difference was found between the sexes.
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The relationship between the concentration of VIIIRAg and VIIICAg was de-
termined using Pearson's coefficient of correlation and was .56 (P < .0001). The
effect of age on VIIICAg could be an effect that was secondary to the effect on
VIIIRAg. The values for VIIICAg were therefore corrected for the correlation
with VIIIRAg (VIIICAgc.rr) by linear regression: In VIIICAgcorr = In VIIICAg
+ 0.696 (mean In VIIIRAg - In VIIIRAg).
After this correction, an age effect was no longer present (table 4). Similarly,
the values for VIIIRAg were corrected for the correlation with VIIICAg
(VIIIRAgcorr): In VIIIRAgcor, = In VIIIRAg + 0.461 (mean ln VIIICAg - In
VIIICAg).
After this correction, an effect of age on VIIIRAg could still be found. Thus,
it seems that the effect of age on FVIII concentration is mainly an effect on
VIIIRAg concentration.
Association to genetic markers. The previously described association between
plasma concentration of factor VIII and ABO blood type [2, 4, 14] was confirmed
in the present study for both VIIICAg and VIIIRAg (table 5). Individuals with
blood type 0 had a significant lower plasma concentration of factor VIII than
individuals with blood type Al or B. Individuals with blood type A2 had a con-
centration that was intermediate between individuals with blood type 0 and blood
type Al.
A difference as described here could be due to a stratification, that is, the
existence of a subpopulation with a high frequency of blood group 0 and a lower
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FIG. 1.-Distribution of plasma concentration of VIIIRAg according to age and sex
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FIG. 2.-Distribution of plasma concentration of VIIICAg according to age and sex
concentration of factor VIII. If this were the case, one would not expect to find
the differences between type 0 and type A individuals in different populations
or within families. The same difference in VIIIRAg concentration was, however,
also found within families, since it was present in 18 pairs of fraternal twins
where one twin was blood type 0 (mean In VIIIRAg concentration 4.28) and the
other was type Al or B (mean In VIIIRAg concentration 4.67).
Like the effect of age, the effect of ABO blood type on VIIICAg could be
secondary to an effect on VIIIRAg. When VIIICAg values that had been corrected
for VIIIRAg effect were used, an association to ABO blood type was no longer
present. When, similarly, VIIIRAg values were corrected for VIIICAg effect, a
significant effect on ABO blood type on VIIIRAg concentration was still present
(table 5).
No other significant association was found among plasma concentrations of
VIIICAg, VIIIRAg, or IXAg and any of the other markers used for zygosity
testing.
Estimation of Genetic Variance by Model-fitting
VIJIRAg and VIJICAg. The mean squares for VIIIRAg and VIIICAg are shown
in table 6. A model including only VEW or both VEW and VEB could be discarded.
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A model including VG, VEW, and VEB gave a negative estimate of VEB. A model
including VG and VEW gave the best fit. Very similar estimates of heritability
were obtained when the analyses were performed separately for young and old
twins. The estimates given in table 7 were therefore determined on the total
material after correction for age effect by z-scoring.
We found a major effect of ABO blood type on factor VIII concentration. We
therefore calculated the fraction of the genetic variance that was due to the variation
in ABO blood type, again using analysis of variance. As can be seen from table
8, 30% of the genetic variance of VIIIRAg and 12% of the genetic variance of
VIIICAg could be explained by ABO blood type.
Since the effect of ABO blood type on VIIICAg was secondary to an effect on
VIIIRAg, the genetic variance due to ABO blood type was also determined on
VIIICAg values that had been corrected for effect on VIIIRAg. As expected, a
genetic variance due to ABO blood type could no longer be detected (table 8).
Correlation of VIIICAg between DZ Twin Pairs
Mather and Links [15] showed that for sex-linked variables the sister-sister
correlations are higher than the brother-brother correlations. Filippi et al. [3]
found that the variation of VIIIC in normal individuals was largely controlled
by a series of X-linked isoalleles. We therefore compared the intraclass correlation
Distribution of IXAg in 333 twins
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EFFECT OF AGE AND SEX ON PLASMA FACTOR VIII AND FACTOR IX CONCENTRATION
VIIIRAg VIIICAg IX
SEX AGE (YRs) No. Mean (ln%) No. Mean (ln%) No. Mean (%)
Females ...... 33-39 79 4.29 ± 0.05 80 4.66 ± 0.06 79 90 ± 2.26
Females ...... 57-62 95 4.57 ± 0.05 84 4.92 ± 0.06 95 105 ± 2.29
Males ........ 33-39 72 4.28 ± 0.05 66 4.71 ± 0.08 72 97 ± 2.45
Males ........ 57-62 87 4.60 ± 0.05 85 5.04 ± 0.06 87 105 ± 2.29
Total .333 4.447 ± 0.03 315 4.841 ± 0.03 333 100 ± 1.21
F test . .P < .00001 P = .00005 P < .00001
of VIIICAg, which is the X-linked protein, in female and male DZ twin pairs.
As can be seen from table 9, no difference was found.
FIX
For factor IX, no sex effect was apparent and no difference between total
variances for young and old twins was found. Although the distribution was
moderately skewed, this was much less marked than for factor VIII (fig. 3).
Therefore, the data were not transformed, and models were fitted to the whole
set of data. Again, a model including VEW only did not explain the variation.
However, the model with VEW and VEB could not be discarded (X2 = 4.42; P >
.5) and the model with VG and VEW gave no better fit (X2 = 6.61; P > .25). The
full model of VG, VEW, and VEB gave a chi-square of 3.14 (5 df; P > .5) (table
7). Since the estimate of genetic variance of .20 is not significantly different
from zero, the heritability estimate of .20 permits no definite interpretation.
DISCUSSION
The present data show that there is a wide range in plasma concentration of
VIIIRAg and VIIICAg in individuals without symptoms of a bleeding disorder.
For VIIIRAg, the widest range was found in older twins, which was expected
since several diseases are known to influence the level of VIIIRAg [16]. It was
surprising, however, to find a large number of individuals with less than 40%
VIIIRAg and no signs of a bleeding disorder. It is possible that further studies
on these individuals might reveal mild cases of von Willebrand disease, which
is characterized by a low concentration of VIIIRAg.
For both coagulation factors, a higher mean was found in the older- than in
the younger-age group. This age effect is in agreement with a previous study
[17] where an increase in the concentration of VIIIC of 0.8% per year was found.
We found the effect of age to be mainly an effect on VIIIRAg concentration.
VIIIRAg is synthesized in vascular endothelial cells, whereas VIIICAg, according
to one recent report, is synthesized in hepatic sinusoidal endothelial cells [18].
A higher plasma concentration in older individuals might be due to damage to
endothelial cells and a leakage of VIIIRAg into plasma [ 19]. A similar mechanism
has been invoked to explain the increased concentration of VIIIRAg in individuals
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TABLE 8
ESTIMATE OF GENETIC VARIANCE IN FACTOR VIII CONCENTRATION DUE TO ABO BLOOD TYPE
VI1IRAg VIIICAg
VIIIRAg corrected for VIIICAg VIIICAg corrected for VIIIRAg
Variance within ABO blood
type VABO ............. 0.8133 0.5877 0.9401 0.7014
Total variance V .......... 0.9975 0.6668 1.0018 0.7121
Genetic variance VG ...... 0.6155 0.4254 0.5056 0.2691
V - VABO ... 0.30 0.19 0.12 0.04
VG
with diabetes [20]. The plasma concentration of VIIIRAg may, thus, be an indicator
of endothelial damage [ 19].
The association between plasma factor VIII concentration and ABO blood type
was found to be mainly an effect of ABO genes on VIIIRAg (table 5). The plasma
concentration of factor VIII seems to be inversely related to the amount of H
antigen (table 5), as the descending order of strength of H is 0, A2, B, Al [21].
Recently, Sodetz et al. [22] demonstrated that purified factor VIII possesses
covalently bound oligosaccharides with A, B, and H blood group activities. It
remains to be explained, however, how this finding can be related to the higher
VIIIRAg concentration in individuals with blood type A. VIIIRAg is essential
for platelet adhesion to vascular subendothelium. A lower risk of myocardial
infarction [23] and atherosclerosis [24] has been found in persons with blood
type 0 compared to blood type A. The possibility therefore existed that VIIIRAg
is a risk factor for the development of coronary heart disease. However, the
Northwick Park Heart Study, a prospective study of cardiovascular death, showed
that VIIIC but not VIIIRAg was a risk factor [25]. It therefore does not seem
probable that the lower risk for myocardial infarction in blood type 0 individuals
could be explained by the associated low VIIIRAg concentration.
Twin studies are suitable to estimate the strength of the genetic influence but
cannot give information on the mode of inheritance. Current information on the
genetic control of the factor VIII complex was recently reviewed by Graham [5].
At least four genetic variants that affect factor VIII are known: classical X-linked
hemophilia A, a dominant hemophilia A [26], dominant von Willebrand disease,
and the combined factor V/factor VIII deficiency [27]. The genetic influence on
the plasma concentration of VIIIRAg could be due to the existence of several
TABLE 9
INTRACLASS CORRELATION FOR VIIICAg
IN DZ TWIN PAIRS
Age (yrs) Females Males
33-39 ......... .213 .283
57-62 ......... .396 .354
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alleles at each of these loci, in addition to the effect of the ABO locus and other
unknown loci. This is in agreement with previous family studies [1]. We found
no support in our material for a large effect of X-linked isoalleles on the normal
variation of VIIICAg (table 9) as was found by Filippi et al. [3] for VIIIC.
However, our study was designed to estimate the heritability of factor VIII, and
a significant effect of X-linked alleles on VIIICAg cannot be excluded. Furthermore,
it is possible that a different result would be obtained if VITIC instead of VIIICAg
had been determined. The normal variation in factor VIII level may well be due
to the effect of many autosomal genes in addition to X-linked isoalleles.
The relationship between IXAg and IXC seems to be a simple one, and the
coefficient of correlation between the plasma concentration of IXC and IXAg is
high [28]. Our present study gave no indication of a significant genetic influence
on the plasma concentration of IXAg. Thus far, our knowledge of the loci affecting
the factor IX molecule is limited to the X-linked locus for hemophilia B. However,
Lester et al. [29] found a possible bimodality in the distribution of IXC in 206
young men, with only 2% of individuals belonging to the distribution with the
highest activity. The number of male twin pairs in each age group in our present
study was too small to uncover such a bimodality.
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